Published in

American Association for the Advancement of Science, Science, 6504(369), p. 643-650, 2020

DOI: 10.1126/science.abc5902

Links

Tools

Export citation

Search in Google Scholar

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

Journal article published in 2020 by Philip J. M. Brouwer ORCID, Tom G. Caniels ORCID, Karlijn van der Straten ORCID, Jonne L. Snitselaar, Yoann Aldon ORCID, Sandhya Bangaru, Jonathan L. Torres ORCID, Nisreen M. A. Okba ORCID, Mathieu Claireaux, Gius Kerster, Arthur E. H. Bentlage ORCID, Marlies M. van Haaren, Denise Guerra ORCID, Judith A. Burger, Edith E. Schermer and other authors.
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

Sites of vulnerability in SARS-CoV-2 Antibodies that neutralize severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could be an important tool in treating coronavirus disease 2019 (COVID-19). Brouwer et al. isolated 403 monoclonal antibodies from three convalescent COVID-19 patients. They show that the patients had strong immune responses against the viral spike protein, a complex that binds to receptors on the host cell. A subset of antibodies was able to neutralize the virus. Competition and electron microscopy studies showed that these antibodies target diverse epitopes on the spike, with the two most potent targeting the domain that binds the host receptor. Science , this issue p. 643